Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
3-[(9H-fluoren-9-ylideneamino)oxy]propanoic acid
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
A synthetic small molecule belonging to the class of fluorenes, specifically a fluorene-based aminooxy propanoic acid derivative. It is an experimental compound with no approved medical indications or known clinical use. Its mechanism of action and pharmacological properties are not well characterized in the literature. The compound has been studied as a ligand in structural biology and may interact with proteins such as transthyretin, but its biological activity remains largely unreported[1][2][4].
- Other names
- 3-(fluoren-9-ylideneamino)oxypropanoic acid3-{[(9H-fluoren-9-ylidene)amino]oxy}propanoic acid3-(Fluoren-9-yldieneaminooxy)-propionic acidPropanoic acid, 2-(fluorenylideneaminooxy)-
02
Targets
TTR (Transthyretin)
Beyond the preview
Go deeper on 3-[(9H-fluoren-9-ylideneamino)oxy]propanoic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 3-[(9H-fluoren-9-ylideneamino)oxy]propanoic acid.